Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7683-7691

  Barclay, Christie ^a   Li, Audrey W ^a   Geldenhuys, Laurette ^a   Baguma Nibasheka, Mark ^a   Porter, Geoffrey A ^a   Veugelers, Paul J ^b   Murphy, Paul R ^a   Casson, Alan G ^a,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; COMPLEMENTARY RNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; FGF 2 GENE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME;

EID: 27744587931     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0771     Document Type: Article

References (58)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003:349:2241-52.
2. Blot WJ, Mc Laughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
3. Powell J, McConkey CC, Gillison EW, Spychal RT. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer 2002;102:422-7.
4. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996;7:322-7.
5. Powers CJ, McLesky SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-97.
6. Iida S, Katoh O, Tokunaga A, Terada M. Expression of fibroblast growth factor gene family and its receptor gene family in the human upper gastrointestinal tract. Biochem Biophys Res Commun 1994;199:1113-9.
7. Lord RVN, Park JM, Wickamasinghe K, et al. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003;125:246-53.
8. Hammonud ZT, Kaleem Z, Cooper JD, Sundaresan S, Patterson GA, Goodfellow PJ. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996;56:4499-502.
9. Riegman PHJ, Vissers KJ, Alers JC, et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 2001;61:3164-70.
10. Doak SH, Jenkins GJS, Parry EM, et al. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut 2003;52:623-8.
11. Li AW, Murphy PR. Expression of alternatively spliced FGF-2 antisense RNA transcripts in the central nervous system: regulation of FGF-2 mRNA translation, Mol Cell Endocrinol 2000;170:233-42.
12. Kimelman D, Kirschner MW. An antisense messenger RNA directs the covalent modification of the transcript encoding fibroblast growth factor in Xenopus oocytes. Cell 1989;59:687-96.
13. Murphy PR, Knee R, Li A. Regulation of gene expression in the CNS by natural antisense RNAs. In: Leslie R, editor. Antisense knockdown in the CNS. Oxford: Oxford University Press; 1999. p. 180-94.
14. Knee RS, Pitcher SE, Murphy PR. Basic fibroblast growth factor sense (FGF) and antisense (GFG) RNA transcripts are expressed in unfertilized human oocytes and in differentiated adult tissues. Biochem Biophys Res Commun 1994;205:577-83.
15. Savage MP, Fallen JF. FGF-2 mRNA and its antisense message are expressed in a developmentally specific manner in the chick limb bud and mesonephros. Dev Dyn 1995;202:343-53.
16. Knee R, Li AW, Murphy PR. Characterization and tissue-specific expression of the rat basic fibroblast growth factor antisense mRNA and protein. Proc Natl Acad Sci U S A 1997;94:4943-7.
17. Gagnon ML, Moy GK, Klagsbrun M. Characterization of the promoter for the human antisense fibroblast growth factor-2 gene; regulation by Ets in Jurkat T cells. J Cell Biochem 1999;72:492-506.
18. Mihalich A, Reina M, Mangioni S, et al. Different basic fibroblast growth factor and fibroblast growth factor-antisense expression in eutopic endometrial stromal cells derived from women with and without endometriosis. J Clin Endocrinol Metab 2003;88:2853-9.
19. Li AW, Too CKL, Murphy PR. The basic fibroblast growth factor (FGF-2) antisense RNA (GFG) is translated into a MufT-related protein in vivo. Biochem Biophys Res Commun 1996;223:19-23.
20. Li AW, Too CKL, Knee R, Wilkinson M, Murphy PR. FGF-2 antisense RNA encodes a nuclear protein with MutT-like antitumor activity. Mol Cell Endocrinol 1997;133:177-82.
21. Cai J-P, Kakuma T, Tsuzuki T, Sekiguchi M. cDNA and genomic sequences for rat 8-oxo-dGTPase that prevents occurrence of spontaneous mutations due to oxidation of guanine nucleotides. Carcinogenesis 1995;16:2243-50.
22. Casson AG, Darnton SJ, Subramanian S, Hiller L. What is the optimum distal resection margin for esophageal carcinoma? Ann Thorac Surg 2000;69:205-9.
23. Casson AG, Porter GA, Veugelers PJ. Evolution and critical appraisal of anastomotic technique following resection of esophageal adenocarcinoma. Dis Esophagus 2002;15:296-302.
24. Sobin LH, Wittekind C, editors. In: TNM classification of malignant tumors. 6th ed. New-York: Wiley-Liss; 2002. p. 60-4.
25. Casson AG, Evans SC, Gillis A, et al. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 2003;125:1121-31.
26. Baguma-Nibasheka M, Li A, Osman MS, et al. Coexpression and regulation of the FGF-2 and FGF antisense genes in leukemic cells. Leuk Res 2005;29:423-33.
27. Quarto N, Talarico D, Sommer A, Florkiewicz R, Basilico C, Rifkin DB. 1989 Transformation by basic fibroblast growth factor requires high levels of expression: comparison with transformation by hst/K-fgf. Oncogene Res 1989;5:101-10.
28. Murphy PR, Sato Y, Knee R. Phosphorothioate antisense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage-independent growth of a malignant glioblastoma cell line. Mol Endocrinol 1992;6:877-84.
29. Kumar M, Carmichael GG. Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Microbiol Mol Biol Rev 1998;62:1415-34.
30. Kumar M, Carmichael GG. Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts. Proc Natl Acad Sci U S A 1997;94:3542-7.
31. McCarthy JEG, Kollmus H. Cytoplasmic mRNA-protein interactions in eukaryotic gene expression. TIBS 1995;20:191-7.
32. Sachs A, Wahle E. Poly(A) tail metabolism and function in eukaryotes. J Biol Chem 1993;268:22955-8.
33. Siebel C, Kanaar R, Rio D. Regulation of tissue-specific P-element pre-mRNA splicing requires the RNA-binding protein PSI. Genes Dev 1994;8:1713-25.
34. Singer R. RNA zipcodes for cytoplasmic addresses. Curr Biol 1993;3:719-21.
35. Murphy PR, Knee RS. Identification and characterization of an antisense RNA transcript (GFG) from the basic fibroblast growth factor gene in human and rat cells. Mol Endocrinol 1994;8:825-9.
36. Asa SL, Ramyar L, Murphy PR, Li AW, Ezzat S. The endogenous fibroblast growth factor-2 antisense gene product regulates pituitary cell growth and hormone production. Mol Endocrinol 2001;15:589-99.
37. Li A, Seyoum G, Shiu R, Murphy PR. Expression of the rat bFGF antisense RNA transcript is tissue-specific and developmentally regulated. Mol Cell Endocrinol 1996;118:113-23.
38. Volk R, Koster M, Poting A, Hartmann L, Knochel W. An antisense transcript from the Xenopus laevis bFGF gene coding for an evolutionary conserved 24 kd protein. EMBO J 1989;8:2983-8.
39. Bessman MJ, Frick DN, O'Handley SF. The MutT proteins or "Nudix" hydrolases, a family of versatile, widely distributed, "housecleaning" enzymes. J Biol Chem 1996;271:25059-62.
40. Michaels ML, Tchou J, Grollman AP, Miller JH. A repair system for 8-oxo-7,8-dihydrodeoxyguanine. Biochemistry 1992;31:10964-8.
41. Safrany ST, Caffrey JJ, Yang X, et al. A novel context for the "MufT" module, a guardian of cell integrity, in a diphosphoinositol polyphosphate phosphohydrolase. EMBO J 1998;17:6599-607.
42. Hua LV, Green M, Warsh JJ, Li PP. Molecular cloning of a novel isoform of diphosphoinositol polyphosphate phosphohydrolase: a potential target of lithium therapy. Neuropsychopharmacology 2001;24:640-51.
43. Caffrey JJ, Safrany ST, Yang X, Shears SB. Discovery of molecular and catalytic diversity among human diphosphoinositol-polyphosphate phosphohydrolases. An expanding nudt family. J Biol Chem 2000;275:12730-6.
44. McLennan AG. The MutT motif family of nucleotide phosphohydrolases in man and human pathogens [review]. Int J Mol Med 1999;4:79-89.
45. Yang H, Slupska MM, Wei YF, et al. Cloning and characterization of a new member of the Nudix hydrolases from human and mouse. J Biol Chem 2000;275:8844-53.
46. Perraud AL, Fleig A, Dunn CA, et al. ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature 2001;411:595-9.
47. Piccirillo C, Khanna R, Kiledjian M. Functional characterization of the mammalian mRNA decapping enzyme hDcp2. RNA 2003;9:1138-47.
48. Tsuzuki T, Egashira A, Igarashi H, et al. Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase. Proc Natl Acad Sci U S A 2001;98:11456-61.
49. van Lanschot JJB, Gonzalez DG, Richel DJ. Surgery, radiotherapy, and chemotherapy for esophageal carcinoma. Curr Opin Gastroenterol 2001;17:400-5.
50. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
51. Bosset J-F, Gignoux M, Triboulet J-P, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 1997;337;161-7.
52. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84.
53. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002;359:1727-33.
54. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754-61.
55. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-43.
56. Song S, Wientjes MG, Gan Y, Au JLS. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A 2000;97:8658-63.
57. Coleman AB. Positive and negative regulation of cellular sensitivity to anti-cancer drugs by FGF-2. Drug Resist Updat 2003;6:85-94.
58. Li AW, Watanabe C, Casson AG, Murphy PR. FGF-2 modulates sensitivity to anticancer drugs in esophageal adenocarcinoma cell lines [abstract]. Proc Am Assoc Cancer Res 2005;46:LB263.